BlueCrest Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlueCrest Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,087	Closed	-$362K	–	1169
2015 Q4	$362K	Buy	+4,087	New	+$323K	0.02%	677
2015 Q2	–	Sell	-7,755	Closed	-$325K	–	946
2015 Q1	$325K	Buy	+7,755	New	+$220K	0.02%	514

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

BlueCrest Capital Management's EGRX Position: Q1 2016 in Review

BlueCrest Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2016, closing a stake of 4,087 shares — an estimated $362K sold.

BlueCrest Capital Management first reported a position in EGRX in Q1 2015 and held it in 2 quarters. The position peaked at $362K in Q4 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q1 2016.

BlueCrest Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
BlueCrest Capital Management sold 4,087 Eagle Pharmaceuticals, Inc. shares in Q1 2016, an estimated $362K.
BlueCrest Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
BlueCrest Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $362K in Q4 2015.
119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2016.

Based on BlueCrest Capital Management's 13F filing for Q1 2016, filed 3 May 2016.